Loading data for FATE — first visit, this takes a few seconds.
Fate Therapeutics, Inc. (FATE)
NasdaqGM: FATE
· 实时价格 · USD
2.50
+0.02 (0.81%)
收盘价： Sep 08, 2026, 3:59 PM
股价、关键数字和最新消息，都在这一页。
Fate Therapeutics, Inc.（FATE）股价、分析与数据
0.81% (1D)
| 买价 | 1.91 |
| 市值 | 293M |
| 营收（TTM） | 6.49M |
| 净利润（TTM） | -126M |
| 2.55 | |
| -1.05 | |
| n/a | |
| -2.53 | |
| 市净率（TTM） | 1.86 |
| 市销率（TTM） | 45.13 |
| 财报日期 | Nov 12, 2026 |
| 卖价 | 3.28 |
| 成交量 | 1,918,064 |
| 20日均量 | 2,870,190 |
| 开盘价 | 2.44 |
| 前收盘价 | 2.48 |
| 日内区间 | 2.40 - 2.55 |
| 52周区间 | 0.93 - 3.23 |
| 分析师 | n/a |
| 目标价 | n/a |
| 分红 | n/a |
| 除息日 | n/a |
关于 FATE
Fate Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops programmed cellular immunotherapies for cancer and immune disorders in the United States and internationally. The company's chimeric antigen receptor (CAR)-targeted NK and T-cell product candidates include FT836 which is in preclinical stage for multiple tumor types; and FT522, to treat B-cell Lymphoma and autoimmunity. Its CAR T-cell programs include FT819 to treat sys...
公司完整简介财报意外
Fate Therapeutics 已于 Aug 13, 2026 发布季度财报：
- 营收为 $2.08M 低于预期 $0, ， 9.18% 同比增长.
- 每股收益为 -0.25 超出预期 0.01, ， 13.79% 同比增长.
第 1 页，共 2 页